Thomas Jefferson University

Jefferson Digital Commons
Department of Psychiatry and Human Behavior Department of Psychiatry and Human Behavior
Faculty Papers
5-1-2020

Results of the ADHERE upper airway stimulation registry and
predictors of therapy efficacy.
Erica Thaler
Richard Schwab
Joachim Maurer
Ryan Soose
Christopher Larsen

See next page for additional authors

Follow this and additional works at: https://jdc.jefferson.edu/phbfp
Part of the Psychiatry Commons

Let us know how access to this document benefits you
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Psychiatry and Human Behavior Faculty Papers by an authorized
administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.

Authors
Erica Thaler, Richard Schwab, Joachim Maurer, Ryan Soose, Christopher Larsen, Suzanne Stevens,
Damien Stevens, Maurits Boon, Colin Huntley, Karl Doghramji, Tina Waters, Alan Kominsky, Armin Steffen,
Eric Kezirian, Benedikt Hofauer, Ulrich Sommer, Kirk Withrow, Kingman Strohl, and Clemens Heiser

Results of the ADHERE Upper Airway Stimulation Registry and
Predictors of Therapy Efﬁcacy
Erica Thaler, MD ; Richard Schwab, MD; Joachim Maurer, MD; Ryan Soose, MD; Christopher Larsen, MD;
Suzanne Stevens, MD; Damien Stevens, MD; Maurits Boon, MD; Colin Huntley, MD ; Karl Doghramji, MD;
Tina Waters, MD; Alan Kominsky, MD; Armin Steffen, MD ; Eric Kezirian, MD ;
Benedikt Hofauer, MD ; Ulrich Sommer, MD; Kirk Withrow, MD; Kingman Strohl, MD;
Clemens Heiser, MD
Objective/Hypothesis: The ADHERE Registry is a multicenter prospective observational study following outcomes of
upper airway stimulation (UAS) therapy in patients who have failed continuous positive airway pressure therapy for obstructive sleep apnea (OSA). The aim of this registry and purpose of this article were to examine the outcomes of patients receiving
UAS for treatment of OSA.
Study Design: Cohort Study.
Methods: Demographic and sleep study data collection occurred at baseline, implantation visit, post-titration (6 months),
and ﬁnal visit (12 months). Patient and physician reported outcomes were also collected. Post hoc univariate and multivariate
analysis was used to identify predictors of therapy response, deﬁned as ≥50% decrease in Apnea-Hypopnea Index (AHI) and
AHI ≤20 at the 12-month visit.
Results: The registry has enrolled 1,017 patients from October 2016 through February 2019. Thus far, 640 patients have
completed their 6-month follow-up and 382 have completed the 12-month follow-up. After 12 months, median AHI was
reduced from 32.8 (interquartile range [IQR], 23.6–45.0) to 9.5 (IQR, 4.0–18.5); mean, 35.8  15.4 to 14.2  15.0, P < .0001.
Epworth Sleepiness Scale was similarly improved from 11.0 (IQR, 7–16) to 7.0 (IQR, 4–11); mean, 11.4  5.6 to 7.2  4.8,
P < .0001. Therapy usage was 5.6  2.1 hours per night after 12 months. In a multivariate model, only female sex and lower
baseline body mass index remained as signiﬁcant predictors of therapy response.
Conclusions: Across a multi-institutional study, UAS therapy continues to show signiﬁcant improvement in subjective
and objective OSA outcomes. This analysis shows that the therapy effect is durable and adherence is high.
Key Words: Obstructive sleep apnea, surgery, upper airway stimulation, drug-induced sleep endoscopy.
Level of Evidence: 2
Laryngoscope, 130:1333–1338, 2020

INTRODUCTION
Obstructive sleep apnea (OSA) is a disorder characterized by repetitive collapse of the upper airway during sleep
with consequences of nocturnal hypoxemia and recurrent
arousals from sleep.1 There is increasing evidence that
those with moderate to severe sleep apnea, as deﬁned by
an Apnea-Hypopnea Index (AHI) value >15 events per hour

of sleep, more often experience sequelae of sleep apnea,
including daytime sleepiness and cardiovascular morbidity
and mortality.2 The gold standard for treatment of OSA
is considered to be continuous positive airway pressure
(CPAP).3 However, approximately one-third of patients
have such difﬁculty with its chronic use that they seek
other options or choose to remain untreated. Upper airway
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METHODS
The ADHERE registry is an ongoing international, multicenter prospective observational study. The registry collects patient
and physician reported outcomes after UAS implantation. The registry was approved by ethics committees or institutional review
boards at every implantation center. The study was registered with
ClinicalTrials.gov (http://www.clinicaltrials.gov, NCT02907398).

Upper Airway Stimulation System
The UAS system (Inspire Medical Systems Inc., Maple Grove,
MN) consists of a respiration sensor, programmable implanted
pulse generator (IPG), and stimulating electrodes. The sensor
detects respiratory efforts from the chest that are analyzed by the
IPG. The IPG delivers stimulation synchronized with each respiratory cycle to the anterior branches of the hypoglossal nerve. Upon
stimulation, these nerves cause forward protrusion of the tongue,
which in turn increases the size of the oropharyngeal airway. Anterior palate movement is commonly coupled with tongue movement.

Device Implantation Procedure
Details of device implantation and activation are described
in detail in prior publications.8 Figure 1 is an updated illustration emphasizing several of the most important proper steps for
identiﬁcation of anterior branching of the hypoglossal nerve. The
posterior edge of the anterior belly of the digastric muscle and

then the posterior edge of the mylohyoid muscle are retracted
anteriorly. Just underneath this, and at the anterior edge of the
submandibular gland, is the hypoglossal nerve as it begins to
divide. The cuff electrode is placed on the genioglossus branches
of the hypoglossal nerve.

Data Collection
The registry enrolls adult participants who meet the
approved indications of UAS including AHI between 15 to
65 events per hour inclusive, who are intolerant to CPAP, and
who are free of complete concentric collapse during sedated
endoscopy. Following baseline and implant data collection, the
registry collects information from two clinical visits during postimplantation follow-up: the post-titration visit, approximately
6 months post-implantation, and the ﬁnal visit, approximately
12 months post-implantation.
During the post-implantation visits, study investigators
determine OSA severity by AHI via either an in-lab attended
polysomnography or a type 3 home sleep apnea test, daytime
sleepiness as reported by participants using the Epworth Sleepiness Scale (ESS), and objective therapy use of hours per night
from data stored in the IPG.

Data Analysis
The AHI and ESS distributions were tested for normality
using the Shapiro-Wilk test, with a signiﬁcance level of 0.05. We
compared outcome measures of AHI and ESS from the ﬁnal visit
with the baseline using the Wilcoxon signed-rank test with continuity correction, with a type I error rate of >0.05. Results are
presented as median and mean  standard deviation. Post hoc
logistic regression analyses included a model of all potential predictors of treatment success using Sher criteria,9 deﬁned as
≥50% reduction to AHI ≤ 20. Sensitivity analysis to two other definitions of AHI therapy success, deﬁned ≥50% reduction to
AHI < 10, and AHI < 10, was performed to conﬁrm the robustness of the predictor ﬁndings. Age, sex, baseline body mass index
(BMI), baseline AHI, therapy usage per week per week at 6 and
12 months, binary therapy use (<28 hours vs. ≥28 hours) at
6 and 12 months, and tongue-motion phenotype at implantation
were entered into the model as potential predictors. An additional multivariate model with stepwise selection was used to
reduce the model to retain only signiﬁcant parameters to assess
for predictors of the therapy. Sex, baseline BMI, and binary therapy use (<28 hours vs ≥28 hours) at ﬁnal follow-up were entered
into the model in the ﬁrst, second, and third step. No other variable met the χ2 score of 0.2 signiﬁcance level for entry into the
model. The signiﬁcance level of the Wald χ2 for an effect to stay
in the model is 0.05. An odds ratio (OR) <1 indicates success is
less likely, whereas an OR > 1 indicates success is more likely.
A P value <.05 is considered statistically signiﬁcant.

RESULTS
Participants
Fig. 1. Approach to the anterior branches of the hypoglossal nerve.
The ﬁrst step is to identify and retract the posterior edge of the
anterior belly of the digastric muscle (black arrow). The second step
is to identify and anteriorly retract the posterior edge of the
mylohyoid muscle. Just underneath this and at the anterior border
of the submandibular gland is the hypoglossal nerve as it begins to
branch. Genioglossus branches are identiﬁed with nerve stimulation
and a neuromonitor.

The registry has enrolled 1,017 participants from
October 2016 through February 2019. Thus far, 640 participants have completed their 6-month post-titration followup and 382 have completed the 12-month ﬁnal follow-up.
Average age was 60  11 years, BMI of 29.3  3.9 kg/m2,
74% male, and 96% Caucasian. Participants were generally
healthy; the most common baseline comorbidity was hypertension (48%). Prior to implantation, 97% of participants
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stimulation (UAS) with electrical activation of the hypoglossal nerve has been shown to be a safe and effective
treatment option in controlled studies4,5 and post-approval
studies6,7 in clinical practices. This report details the
results of an international registry designed to evaluate
efﬁcacy of UAS in patients with moderate to severe OSA
and those who could not or would not use CPAP as a primary therapy. A second goal was to identify patients who
might be more likely to beneﬁt from UAS.

Fig. 2. Median AHI measurements at baseline and at 6 and
12 months postoperatively. Error bars in SD. AHI = ApneaHypopnea Index; SD = standard deviation.

After receiving the implant, AHI was reduced from
32.8 (interquartile range [IQR], 23.6–45.0) at baseline to
6.3 (IQR, 2–14.8) at 6 months, and 9.5 (IQR, 4.0–18.5) at
12 months (mean, 35.8  15.4 at baseline to 11.0 
13.5 at 6 months and 14.2  15.0 at 12 months, P < .001;
Fig. 2). Using Sher criteria9 on patients with baseline and
follow-up AHI data, 83% (n = 485/582) and 69%
(n = 265/381) participants met treatment success after
6 and 12 months, respectively.
Similarly, participants reported reduced daytime
sleepiness with ESS of 11.0 (IQR, 7.0–16.0) at baseline to
7.0 (IQR, 4.0–11.0) at 6 months and 6.0 (IQR, 3.0–10.0) at
12 months (mean, 11.4  5.6 at baseline to 7.7  4.8 at
6 months and 7.2  4.8 at 12 months, P < .0001 comparing with baseline; Fig. 3). Using the normalizing threshold of ESS < 10,10 37%, 67%, and 74% had normal
daytime sleepiness at baseline, 6 months, and 12 months
post-implantation.
After 12 months, the median device report of objective therapy use was 5.7 (IQR, 4.1–7.1; mean, 5.6  2.1)
hours per night; 92% of investigators reported improvement with treatment after participant receiving implantation; 93% of participants reported overall satisfaction
with UAS treatment, 95% preferred UAS over positive
airway pressure, 94% would choose UAS again if asked,
and 96% would recommend UAS to family and friends.

Predictors of Therapy Response
Fig. 3. ESS measurements at baseline and at 6 and 12 months
postoperatively. Error bars in SD. ESS = Epworth Sleepiness Scale;
SD = standard deviation.

reported history of positive airway pressure use for treatment of OSA: 20% with oral appliances, 22% with nasal
procedures, 29% with palatal procedures, and 5% with
tongue-base procedures.

Using logistic regression models, we examined predictors of treatment success based on Sher criteria. In the
univariate analysis, female sex has 90% increased odds of
having a more favorable AHI response compared with
male sex. Each unit decrease of BMI is associated with
8.5% increased odds of having a more favorable AHI
response. Other baseline characteristics of age and baseline AHI did not predict AHI response. Tongue motion
reported from the implantation procedure did not predict

TABLE I.
Predictors of Therapy Response.
Univariate Results

Multivariate Results, Full Model

Multivariate Results, Reduced Model

Parameter

OR (P Value)

95% CI for OR

OR (P Value)

95% CI for OR

OR (P Value)

95% CI for OR

Sex, F vs. M

1.943 (.0457)

1.013-3.729

3.634 (.0041)

1.505-8.772

3.413 (.0049)

1.452-8.019

Age at consent

1.014 (.1862)

0.993-1.034

1.000 (.9998)

0.976-1.025

BMI at baseline

0.915 (.0028)

0.863-0.970

0.913 (.0108)

0.851-0.979

0.909 (.0050)

0.851-0.972

Baseline AHI

0.993 (.2914)

0.979-1.006

1.006 (.5198)

0.988-1.024

Tongue motion
Bilateral protrusion vs. right protrusion

(.6414)
1.312 (.3488)

—
0.743-2.318

(.3795)
1.554 (.1645)

—
0.835-2.894

Bilateral or right protrusion vs. other

0.963 (.9244)

0.442-2.100

—

—

Other vs. right protrusion

1.284 (.5843)

0.525-3.141

1.339 (.6320)

0.406-4.415

Therapy hr/wk at 6 mo
<28 hr vs. ≥28 hr
Therapy hr/wk at 12 mo
<28 hr vs. ≥28 hr

1.011 (.2457)

0.993-1.029

1.004 (.8103)

0.971-1.038

0.726 (.3864)

0.352-1.498

1.130 (.8362)

0.355-3.592

1.017 (.0390)

1.001-1.033

1.001 (.9668)

0.969-1.034

0.622 (.0769)

0.367-1.053

0.651 (.3732)

0.254-1.673

AHI = Apnea-Hypopnea Index; BMI = body mass index; CI = conﬁdence interval; F = female; M = male; OR = odds ratio.
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Treatment Effects

Univariate Results

Multivariate Results, Full Model

Multivariate Results, Reduced Model

Parameter

OR (P Value)

95% CI for OR

OR (P Value)

95% CI for OR

OR (P Value)

95% CI for OR

Sex, F vs. M

2.123 (.0083)

1.213-3.713

3.363 (.0008)

1.651-6.848

2.926 (.0017)

1.494-5.728

Age at consent

1.010 (.3023)

0.991-1.029

0.985 (.2104)

0.963-1.008

BMI at baseline

0.910 (.0008)

0.861-0.961

0.936 (.0466)

0.877-0.999

0.926 (.0153)

0.869-0.985

Baseline AHI

0.974 (.0002)

0.960-0.987

0.981 (.0246)

0.964-0.998

0.980 (.0168)

0.964-0.996

P = .1628

—

P = .1839

—

1.606 (.0902)

0.928-2.778

1.731 (.0765)

0.943-3.176

Tongue motion
Bilateral protrusion vs. right protrusion
Bilateral or right protrusion vs. other

0.723 (.3803)

0.350-1.492

—

—

Other vs. right protrusion

2.011 (.1054)

0.863-4.683

1.994 (.2275)

0.650-6.114

Therapy hr/wk at 6 mo
<28 hr vs. ≥28 hr
Therapy hr/wk at 12 mo
<28 hr vs. ≥28 hr

1.012 (.1569)

0.995-1.029

0.993 (.6620)

0.962-1.025

0.607 (.1670)

0.299-1.232

0.792 (.6829)

0.258-2.430

1.018 (.0211)

1.003-1.033

1.023 (.1456)

0.992-1.055

0.744 (.2494)

0.450-1.230

1.254 (.6228)

0.509-3.086

—
—

—

AHI = Apnea-Hypopnea Index; BMI = body mass index; CI = conﬁdence interval; F = female; M = male; OR = odds ratio.

AHI outcome. In multivariate analysis with only baseline
sex and BMI included, both parameters remain signiﬁcantly associated with the AHI outcome (Table I).
To test the robustness of these predictors, we performed sensitivity analysis by repeating the univariate
and multivariate analysis to two other deﬁnitions of therapy success besides the Sher criteria (e.g., AHI < 10, or
50% reduction of AHI and AHI < 10; Tables II and III).
Using both deﬁnitions, female sex and lower BMI
remained as positive predictors of AHI response. Higher
baseline AHI emerged as a new additional negative predictor of success.
In further comparing female versus male participants, female patients had a statistically signiﬁcant lower
AHI after 12 months of therapy than did male patients.
Female participants were of older age and lower BMI at

TABLE IV.
Comparing Baseline and OSA Characteristics Between Sexes and
Their UAS Response.
P Value

Sex = F

Sex = M

Age, yr

62.9  9.9

59.5  11.5

<.0001

BMI, kg/m2, baseline

28.9  4.5

29.4  3.6

0.04

AHI, events/hr, baseline

34.4  15.6

36.2  15.3

0.11

ESS, baseline

11.4  5.3

11.4  5.7

0.92

AHI, events/hr, 12 mo

10.3  11.0

15.0  15.6

0.02

ESS, 12 mo

7.1  4.3

7.2  4.9

0.88

Therapy use, hr/night, 12 mo

5.9  2.1

5.5  2.1

0.18

AHI = Apnea-Hypopnea Index; ESS = Epworth Sleepiness Scale;
F = female; M = male; OSA = obstructive sleep apnea; UAS = upper airway
stimulation.

TABLE III.
Predictors of Therapy Success, Deﬁned as AHI < 10.
Univariate Results
Parameter

Multivariate Results, Full Model

Multivariate Results, Reduced Model

OR (P Value)

95% CI for OR

OR (P Value)

95% CI for OR

OR (P Value)

95% CI for OR

Sex, F vs. M

2.145 (.0073)

1.228-3.745

3.240 (.0012)

1.592-6.592

2.875 (.0021)

1.467-5.634

Age at consent

1.011 (.2272)

0.993-1.030

0.988 (.3089)

0.966-1.011

BMI at baseline

0.911 (.0010)

0.863-0.963

0.939 (.0571)

0.879-1.002

0.929 (.0201)

0.872-0.988

Baseline AHI

0.972 (<.0001)

0.959-0.986

0.979 (.0126)

0.962-0.995

0.978 (.0085)

0.962-0.994

P = .1466

—

P = .1705

—

Bilateral protrusion vs. right protrusion

1.645 (.0751)

0.951-2.845

1.759 (.0681)

0.959-3.226

Bilateral or right protrusion vs. other

0.737 (.4089)

0.357-1.521

—

—

Other vs. right protrusion

2.011 (.1054)

0.863-4.683

1.975 (.2336)

0.644-6.054

Tongue motion

Therapy hr/wk at 6 mo
<28 hr vs. ≥28 hr
Therapy hr/wk at 12 mo
<28 hr vs. ≥28 hr

1.013 (.1443)

0.996-1.030

0.994 (.7086)

0.963-1.026

0.595 (.1506)

0.293-1.208

0.805 (.7042)

0.262-2.469

1.017 (.0225)

1.002-1.032

1.020 (.2033)

0.989-1.052

0.728 (.2167)

0.441-1.204

1.168 (.7348)

0.475-2.875

—
—

—

AHI = Apnea-Hypopnea Index; BMI = body mass index; CI = conﬁdence interval; F = female; M = male; OR = odds ratio.
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TABLE II.
Predictors of Therapy Success, Deﬁned as 50% Reduction in AHI From Baseline and AHI < 10.

Post-Titration
Type

No. of Events

Final Visit
% of Patients

No. of Events

% of Patients

Tongue weakness

3

<1

0

0

Swallowing or speech related

4

1

1

<1

Discomfort, incision/scar

14

4

8

2

Discomfort, device

10

3

5

1

Infection

2

<1

0

0

Postoperative other*

14

4

6

2

Stimulation-related discomfort

41

12

28

8

Tongue abrasion

12

3

14

4

Insomnia/arousal

10

3

17

5

1

<1

2

<1

Other discomfort

12

3

8

2

Activation, other

37

3

23

7

161

46

113

32

Revision interventions, including explantation

Total

*Postoperative other includes shortness of breath, seroma, numbness of the throat, hoarseness during the day, and a mild tongue-base and epiglottic
obstruction. A total of 71 patients reported adverse events at the post-titration visit and 49 at the ﬁnal visit (not mutually exclusive). Some patients reported multiple adverse events. Percentage of patients was calculated based on the number of patients at each visit who completed the visit form, which contains adverse
event information.

baseline. Female participants showed a trend of higher
therapy use after 12 months (Table IV).

UAS therapy shows durable response in this large
cohort of patients followed for 12 months post-implantation. The ADHERE study group continues to demonstrate
limited adverse events and overall excellent outcomes
both in term of success rates and device utilization. In
addition, patients’ reported reduction in symptomatology
and satisfaction with UAS treatment are signiﬁcant and
durable measures of success.
Although the study cohort’s average age of 60 years
might appear high, age as an independent variable did
not predict response. This ﬁnding contrasts with prior
reporting of the ADHERE registry.8 There may be some
self-selection of patients that skews the population older.
Perhaps older patients are less inclined to pursue ablative procedures. Also, with age, perhaps the presence of
an implanted device in the chest wall is less concerning
than it might be in a younger age cohort. It should be
emphasized that this procedure is not precluded by the
presence of a pacemaker or automated implantable

cardioverter-deﬁbrillator. At this juncture, the authors do
not ﬁnd that age should be a signiﬁcant selection criterion either in favor of or against implantation.
When using the Sher criterion (≥50% reduction in AHI
and ≤ 20) as the basis of therapy response, baseline AHI did
not predict response. However, when using other deﬁnitions
of therapy response, namely AHI < 10, or 50% reduction in
AHI and < 10, baseline AHI did predict response, as did sex
and BMI. This is most likely due to the varying deﬁnitions
of AHI response. Thus, the usefulness of baseline AHI as a
response predictor will depend on the criterion chosen to
deﬁne therapy response. We chose to use the Sher criterion
as it is the most commonly used metric in the surgical sleep
apnea literature. When using this deﬁnition of response,
increasing severity of apnea (within the range enrolled in
this registry) should not preclude the decision for implantation or lessen a patient’s potential for excellent response.
Treatment success at AHI values higher than the range
stipulated by the Stimulation Therapy for Apnea Reduction
(STAR) trial criteria have been reported.11
Not surprisingly, improved outcomes are associated
with a lower BMI. This has been shown to be true for other
OSA surgical procedures,12 and UAS implantation does
not appear to be an exception, despite some prior evidence
to the contrary.13 Although surgical success has been
reported at higher BMIs, the BMI cutoff of 32 by STAR
criteria remains a useful guide for surgical decisionmaking until there are better preoperative assessment
tools available to screen out those patients who would not
succeed with UAS therapy. The drug-induced sleep endoscopy criteria for UAS implantation that excludes circumferential collapse is helpful in screening out only some
patients whose fat distribution contributes to upper airway collapse. Surgeons should be mindful that when considering patients with higher BMI, careful attention to fat
distribution may enhance success.
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Adverse Events
Adverse events are reported in Table V. Stimulationrelated discomfort was the most common complaint
reported by participants, reported by 12% of participants
at 6 months and 8% of participants at 12 months postimplantation. Surgical intervention was required for
device revision in three cases: in one participant due to
stimulation electrode dislodgement within 6 months and
in another two participants with stimulation electrode
repositioning within 12 months.
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TABLE V.
Summary of Postoperative Adverse Events.
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The statistically signiﬁcant improved success rate
with female patients bears further investigation. Unsurprisingly due to the demographics of OSA, this cohort
was a small percentage of the overall group studied.
There is no anatomic explanation for this ﬁnding and no
distinguishing features in the demographics of the female
patients in this study to suggest causality. The small, but
statistically signiﬁcant, difference in BMI at baseline
might account for improved success, in keeping with the
overall incremental improvement in AHI reduction with
lower BMI. It is important to note the trend toward
higher use in female patients, which may also account for
at least some of the improvement in AHI reduction.
The greatest strength of this study is that the
ADHERE registry has a large sample size and is an ongoing effort. Its greatest limitation is that both home and
in-laboratory studies were used in the analysis, with
attendant lack of uniformity of AHI recording. Furthermore, sensitivity analysis using other metrics of outcome
success showed that sex and BMI remained as predictors
of success. Baseline AHI as an outcome predictor depends
on the deﬁnition of outcome success. Home sleep studies
may underestimate AHI—this may have affected both
the pre- and post-implantation studies, though not the
titration studies, which were all done in laboratory.

